Monte Rosa Therapeutics, Inc. (GLUE) News
Follow Monte Rosa Therapeutics, Inc. (GLUE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Monte Rosa Therapeutics Reports Quarterly Results
Monte Rosa Therapeutics reported results for the quarter ended September 30. The supplied text contains no financial figures.
EQUITY | Nov 05, 2026, 07:02 PM UTC
M
Monte Rosa Therapeutics Reports Third-Quarter Earnings
Monte Rosa Therapeutics reported third-quarter earnings, according to the headline and available text.
EQUITY | Nov 05, 2026, 12:58 PM UTC
M
Monte Rosa Therapeutics Reports $54.37M Revenue and $0.03 EPS
A $50 million Novartis milestone for MRT-6160 drove year-over-year growth in collaboration revenue. The company swung to net income from a year-earlier loss, with higher interest income contributing and higher research a
EARNINGS | Nov 05, 2026, 12:26 PM UTC
M
Monte Rosa Therapeutics Reports Third-Quarter 2026 Results and Business Updates
The company said positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic disease.
EQUITY | Nov 05, 2026, 12:19 PM UTC
M
Monte Rosa to Receive $37.5 Million Novartis Milestone Payment
Monte Rosa Therapeutics said it will receive a $37.50 million milestone payment from Novartis for the first patient visit.
EQUITY | Oct 28, 2026, 11:05 AM UTC
M
Monte Rosa Therapeutics Reports Positive Phase 1 MRT-8102 Data
Monte Rosa Therapeutics announced positive GFORCE-1 Phase 1 results for MRT-8102, demonstrating approximately 80-90% NEK7 degradation and broad normalization of ASCVD pathogenic drivers, accompanied by a favorable safety
EQUITY | Oct 01, 2026, 11:43 AM UTC
H
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to
LIVE | Oct 01, 2026, 08:31 AM UTC
H
TABLE-Mrt -2026 div forecast
Sept 30 (Reuters) -Mrt Inc.CONSOLIDATED EARNINGS ESTIMATES(in billions of yen unless specified)Full year to Full year toDec 31, 2026 Dec 31, 2026LATEST PREVIOUSFORECAST FORECASTAnnual Div 5.00 yen NIL-Q2 Div NIL-Q4 Div…
EARNINGS | Sep 30, 2026, 07:01 AM UTC
L
Wedbush keeps Monte Rosa Therapeutics price target at $27.00
Wedbush maintained its $27.00 per-share price target for Monte Rosa Therapeutics, according to ratings actions cited by Benzinga (via TradingView News).
EQUITY | Sep 09, 2026, 12:22 PM UTC
M
Monte Rosa gets $50 million milestone as Novartis starts Phase 2
Monte Rosa said it received a $50 million milestone payment after Novartis started a Phase 2 study of MRT-6160, also known as DDY391, in Sjögren’s disease.
REGULATION | Sep 08, 2026, 11:03 AM UTC
M
GLUE: Monte Rosa starts Phase 2 study of MRT-6160
GLUE-linked disclosure says Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader MRT-6160 (DDY391).
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Monte Rosa reports inducement grants under Nasdaq Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. says it has reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:14 PM UTC
L
GLUE/Monte Rosa reports Nasdaq Rule 5635(c)(4) inducement grants
GLUE says Monte Rosa reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Monte Rosa Therapeutics management to participate in investor conferences
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) said management will participate in upcoming investor conferences, with a webcast of the fireside chat planned.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
GLUE: Monte Rosa Therapeutics to participate in investor conferences
Monte Rosa Therapeutics plans to participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Monte Rosa Therapeutics doses first patient in Phase 2 prostate study
Monte Rosa Therapeutics announces first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancer.
EQUITY | Aug 24, 2026, 11:00 AM UTC
L
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
EQUITY | Jul 27, 2026, 01:20 PM UTC
L
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35.
EQUITY | Jun 30, 2026, 01:54 PM UTC